Pseudopolyps are associated with increased fecal calprotectin levels in patients with Inflammatory Bowel Disease in clinical and endoscopic remission

被引：0
|
作者：
Spigarelli De Rabago, I. [1 ]
Suarez Ferrer, C. [2 ]
Poza Cordon, J. [2 ]
Martin Arranz, E. [2 ]
Sanchez Azofra, M. [2 ]
Rueda Garcia, J. L. [2 ]
Suarez Cabredo, C. G. [1 ]
Hernandez Perez, M. [1 ]
Martin Arranz, M. D. [2 ]
机构：
[1] La Paz Univ Hosp, Gastroenterol, Madrid, Spain
[2] Univ Autonoma Madrid, Hosp la Paz Inst Hlth Res, IdiPAZ La Paz Univ Hosp, Gastroenterol, Madrid, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.337
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P211
引用
收藏
页码：S270 / S271
页数：3
相关论文
共 50 条
  • [21] Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease
    Sipponen, Taina
    Kolho, Kaija-Leena
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (01) : 74 - 80
  • [22] Effectiviness of fecal calprotectin measurement determining deep remission in Inflammatory Bowel Disease
    Sezgin, O.
    Boztepe, B.
    Altintas, E.
    Kanik, E. A.
    Mersin, D. Ovla
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S217 - S218
  • [23] Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
    Pauwels, Renske W. M.
    van der Woude, Christien J.
    Erler, Nicole S.
    de Vries, Annemarie C.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [24] FECAL CALPROTECTIN ACCURATELY PREDICTS SYMPTOMATIC RELAPSE IN CHILDREN AND ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION
    Diederen, Kay
    Hoekman, Daniel R.
    Leek, Arjen
    Wolters, Victorien
    Hummel, Thalia
    De Meij, Tim
    Koot, Bart
    Tabbers, Merit
    Benninga, Marc A.
    Kindermann, Angelika
    GASTROENTEROLOGY, 2017, 152 (05) : S617 - S618
  • [25] Fecal calprotectin accurately predicts symptomatic relapse in children and adolescents with inflammatory bowel disease in clinical remission
    Diederen, K.
    Hoekman, D.
    Leek, A.
    Wolters, V.
    Benninga, M.
    Hummel, T.
    de Meij, T.
    Koot, B.
    Tabbers, M.
    Benninga, M.
    Kindermann, A.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S228 - S228
  • [26] A Functional Medicine Program for Patients With Inflammatory Bowel Disease and Improvement in Fecal Calprotectin Levels
    Strobel, Thomas M.
    Spring, Emily
    Horst, Sara
    Campbell, Sarah
    Robbins, Randi
    Dalal, Robin
    Scoville, Elizabeth
    Pabla, Baldeep
    Schwartz, David
    Beaulieu, Dawn Borromeo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S2156 - S2157
  • [27] Correlation between fecal calprotectin and endoscopic, Clinical and Laboratory markers in patients with inflammatory bowel diseases
    Jiao, Chunhua
    Li, Jiajia
    Zhang, Hongjie
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 154 - 154
  • [28] Fecal Calprotectin as a Predictor of Relapse in Patients With Inflammatory Bowel Disease
    Dai, Cong
    Jiang, Min
    Sun, Ming-Jun
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (08) : 715 - 715
  • [29] Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
    Yarur, A.
    Bruss, A.
    Fox, C.
    Beniwal-Patel, P.
    Patel, A.
    Berens, B.
    Naik, S.
    Stein, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S64 - S65
  • [30] VEDOLIZUMAB LEVELS DURING INDUCTION ARE ASSOCIATED WITH LONG-TERM CLINICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Yarur, Andres J.
    Bruss, Alexandra
    Berens, Brandon
    Fox, Caroline
    Beniwal-Patel, Poonam M.
    Patel, Amir
    Ungaro, Ryan C.
    Dubinsky, Marla
    Naik, Snehal
    Stein, Daniel J.
    GASTROENTEROLOGY, 2018, 154 (06) : S827 - S828
12345